🇮🇹·7h agoIndustry
RECORDATI ANNOUNCES LICENSE AGREEMENT WITH IONIS PHARMACEUTICALS FOR ZILGANERSEN FOR THE TREATMENT OF ALEXANDER DISEASE IN ALL COUNTRIES OUTSIDE THE U.S.
Publisher
R
Recordati
Italy
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Recordati
- Region
- Italy
- Scope
- Industry
- Published
- June 25, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on recordati.com
Leave the platform to read the original full article on the publisher site.
Source: Recordati
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/3h ago
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
Eli Lilly News/3h ago
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
Ipsen/6h ago
Ipsen recognized at LTEN Excellence Awards 2026 for transforming field leadership through coaching
Ipsen RSS/6h ago